Sunshine Biopharma Inc. Common Stock (SBFM)
Stock · NASDAQ · Health Care
$0.222as of 10/16/2026
Price chart
Active signals
SBFM Signal Track Record
How signals performed across all stocks →What SBFM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 26 | -7.4% | 31% | October 5, 2026 |
| Volume Spike | 11 | -8.1% | 27% | October 5, 2026 |
| Bollinger Band Breakout | 10 | -15.5% | 30% | May 4, 2026 |
| Any 20-session window (baseline) | -9.7% | 25% |
Computed by MarketWall from daily closing prices since November 30, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SBFM
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 50
- Website
- www.sunshinebiopharma.com/
Fundamentals
- 1-day range
- $0.4117$0.4999
- Market cap
- $2.97M
- P/E (trailing)
- —
- P/E (forward)
- 0.00
- EPS (trailing)
- $-10.03
- Dividend yield
- —
- Beta
- -8.95
- Avg. volume
- 519.8K
- Dividend pay date
- April 6, 2020
How Sunshine Biopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Apr 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Sunshine Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SBFMSunshine Biopharma Inc. Common Stock$0.222▼ 3.48%Market cap $2.97MP/E —$0.4117$24.3
- SHPHShuttle Pharmaceuticals Holdings Inc. Common Stock$5.08▼ 8.80%Market cap $2.79MP/E 43.60$2.58$55.9
- GRIGRI Bio Inc. Common Stock$1.38▼ 1.43%Market cap $2.74MP/E 0.04$1.36$64.12
- SXTP60 Degrees Pharmaceuticals Inc. Common Stock$0.855▼ 4.89%Market cap $3.28MP/E —$0.835$8.62
- ARTLArtelo Biosciences Inc. Common Stock$2.7▼ 1.46%Market cap $2.62MP/E —$2.92$179.19
- ONCOOnconetix Inc. Common Stock$0.479▼ 12.59%Market cap $3.34MP/E 0.00$0.535$200
- PRFXPRF Technologies Ltd. Ordinary Shares$0.781▼ 7.68%Market cap $3.35MP/E —$0.8099$7.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SBFM Sunshine Biopharma Inc. Common Stock | $2.97M | — | $0.222 | ▼ 3.48% | $0.4117$24.3 |
| SHPH Shuttle Pharmaceuticals Holdings Inc. Common Stock | $2.79M | 43.60 | $5.08 | ▼ 8.80% | $2.58$55.9 |
| GRI GRI Bio Inc. Common Stock | $2.74M | 0.04 | $1.38 | ▼ 1.43% | $1.36$64.12 |
| SXTP 60 Degrees Pharmaceuticals Inc. Common Stock | $3.28M | — | $0.855 | ▼ 4.89% | $0.835$8.62 |
| ARTL Artelo Biosciences Inc. Common Stock | $2.62M | — | $2.7 | ▼ 1.46% | $2.92$179.19 |
| ONCO Onconetix Inc. Common Stock | $3.34M | 0.00 | $0.479 | ▼ 12.59% | $0.535$200 |
| PRFX PRF Technologies Ltd. Ordinary Shares | $3.35M | — | $0.781 | ▼ 7.68% | $0.8099$7.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Sunshine Biopharma Says CEO Steve Slilaty, Holder Of About 97% Of Voting Power, Approved Reverse Stock Split Of Up To 1-For-20 By Written ConsentBenzinga · 9/16/2026
- Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling StudiesYahoo · 9/16/2026
- EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling StudiesYahoo · 9/16/2026
Insider Activity
Insider Actions →- David Natan · August 7, 2026 · Grant58.3K
- David Natan · April 14, 2026 · Grant100.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Sunshine Biopharma Amends Charter for Reverse Split
Sunshine Biopharma has amended its articles of incorporation to permit a reverse stock split of up to 1-for-20. The company's board of directors retains discretion on whether and when to execute this action. This move typically aims to adjust the share price to meet listing requirements or improve market perception.
Sunshine Biopharma Amends Charter for Reverse Split. Sunshine Biopharma has amended its articles of incorporation to permit a reverse stock split of up to 1-for-20. The company's board of directors retains discretion on whether and when to execute this action. This move typically aims to adjust the share price to meet listing requirements or improve market perception.